Kosin Medical Journal

Gout in the era of multimorbidity: pathogenesis, systemic comorbidities, and evolving therapeutic strategies: Phillip J Kim, Jihun Kang, Jesang Yu, Geun-Tae Kim, Yunkyung Kim; Kosin Med J. 2026;41(1):26-36. Published online March 31, 2026; DOI: https://doi.org/10.7180/kmj.26.159

3,649 View
37 Download

Abstract PDF PubReader: Gout is the most prevalent inflammatory arthritis worldwide and represents a growing global health burden. It arises from hyperuricemia resulting from disordered purine metabolism, leading to monosodium urate (MSU) crystal deposition and recurrent inflammatory arthritis. Although hyperuricemia is the principal risk factor, genetic susceptibility, impaired urate transport, and emerging factors such as the gut microbiota also contribute to disease development. Acute flares are mediated by MSU crystal-induced activation of the NLRP3 inflammasome and subsequent interleukin-1β production, whereas chronic inflammation results in tophus formation and structural joint damage. Gout is closely associated with metabolic syndrome, chronic kidney disease, and cardiovascular disease, which contribute to persistently elevated mortality. Although advances in imaging and pharmacologic therapy have improved diagnosis and management, the real-world use of urate-lowering therapy remains suboptimal. Further research and sustained efforts by healthcare professionals are needed to improve long-term disease control.

IgA nephropathy in a patient with ankylosing spondylitis well controlled with etanercept: Do-Hyeong Lee, Geun-Tae Kim, Na-Kyoung Hwang, Eun-Heui Kim; Kosin Med J. 2018;33(1):85-90. Published online June 30, 2018; DOI: https://doi.org/10.7180/kmj.2018.33.1.85

7,133 View
20 Download
1 Citations

Ankylosing spondylitis (AS) can involve the eye, gastrointestinal system, cardiopulmonary system, skin, kidneys, and spinal and peripheral joints. It is rarely accompanied by immunoglobulin A (IgA) nephropathy. Although IgA is involved in both AS and IgA nephropathy, the relationship between these diseases remains unclear. We detected hematuria and proteinuria in a 32-year-old male patient with ankylosing spondylitis that remained stable for 4 years through treatment with etanercept, a tumor necrosis factor-α (TNF-α) inhibitor, and diagnosed IgA nephropathy through a renal biopsy. IgA nephropathy seems to be less commonly associated with AS disease activity or specific treatment such as TNF-α inhibitor use.

Citations

Citations to this article as recorded by

IgA Nephropathy—Ankylosing Spondylitis–Associated or Adalimumab-Induced?
Joana Ricardo Pires, Anabela Tavares Valadão Barcelos
JCR: Journal of Clinical Rheumatology.2021; 27(8S): S449. CrossRef

Active Tuberculosis Occurred in Rheumatoid Arthritis Patient Who is Treated with Etanercept after Antituberculosis Chemoprophylaxis with Rifampin: Hae Won Lee, Tae Hwa Lee, Geun-Tae Kim; Kosin Med J. 2010;25(2):203-207. Published online December 31, 2010

747 View
0 Download

PDF

Search